A Safety and Efficacy Follow-up Study With Levetiracetam in Children (4-17 Years Old) Suffering From Absence Seizures
This study has been completed.
Sponsor:
UCB, Inc.
Information provided by:
UCB, Inc.
ClinicalTrials.gov Identifier:
NCT00545012
First received: October 15, 2007
Last updated: September 9, 2009
Last verified: September 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This long-term open label follow-up trial gave pediatric subjects suffering from typical absences in CAE or JAE the opportunity to continue levetiracetam treatment after participation in the pilot study (study N162) or the double-blind study (study N163). Safety and efficacy data were obtained.
Condition | Intervention | Phase |
---|---|---|
Absence Seizures |
Drug: Levetiracetam |
Phase 2 |
Study Type: | Interventional |
Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
Official Title: | A 30-month Safety and Efficacy Follow-up Study With Levetiracetam at Individualized Optimal Dose in Children (4-17 Years Old at Inclusion) Suffering From Typical Absences in Childhood Absence Epilepsy (CAE) or Juvenile Absence Epilepsy (JAE) |
Resource links provided by NLM:
Further study details as provided by UCB, Inc.:
Primary Outcome Measures:
- Continue levetiracetam treatment after participation in the pilot-study N162 or in study N163; Assess long-term safety profile and efficacy of levetiracetam
Enrollment: | 4 |
Study Start Date: | May 2000 |
Study Completion Date: | May 2003 |
Primary Completion Date: | May 2003 (Final data collection date for primary outcome measure) |
Eligibility
Ages Eligible for Study: | 4 Years to 17 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Male/female 4-17 years old having participated in study N162 or in study N163
- suffering from typical absences with 3 Hz spike-wave discharges, with or without tonic-clonic seizures, in CAE or JAE
- expected reasonable benefit (efficacy and tolerability) of levetiracetam long term administration
Exclusion Criteria:
- allergy/intolerance to pyrrolidine derivatives and/or excipients
- use of > 2 concomitant antiepileptic treatment or valproate, ethosuximide or lamotrigine
Contacts and Locations
More Information
No publications provided
Keywords provided by UCB, Inc.:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 17, 2012
No publications provided
ClinicalTrials.gov Identifier: | NCT00545012 History of Changes |
Other Study ID Numbers: | N164 |
Study First Received: | October 15, 2007 |
Last Updated: | September 9, 2009 |
Health Authority: | Belgium: Federal Agency for Medicinal Products and Health Products |
Keywords provided by UCB, Inc.:
Levetiracetam Keppra |
Additional relevant MeSH terms:
Epilepsy, Absence Seizures Stress, Psychological Epilepsy, Generalized Epilepsy Brain Diseases Central Nervous System Diseases Nervous System Diseases Neurologic Manifestations Signs and Symptoms Behavioral Symptoms |
Etiracetam Piracetam Anticonvulsants Central Nervous System Agents Therapeutic Uses Pharmacologic Actions Nootropic Agents Neuroprotective Agents Protective Agents Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on October 17, 2012